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Abstract
Background: Exposure to perfluorinated-alkyl-acids (PFAAs) is ubiquitous. PFAAs are hormone-disrupting
compounds that are strongly suspected to affect mother-child-health such as fetal growth. Thyroid disruption is a
plausible mechanism of action. We aim to summarize the epidemiological evidence for the relation between
prenatal and postnatal exposure to PFAAs and disruption of thyroid homeostasis in mothers and/or infants.
Method: Fifteen original publications on PFAAs concentrations and thyroid hormones (TH) in pregnant women
and/or infants were found upon a literature search in the PubMed database. Information on exposure to seven
PFAAs congeners [Perfluorooctane sulfonate (PFOS), Perfluorooctanoate (PFOA), Perfluorohexane sulfonate (PFHxS),
Perfluorononanoic acid (PFNA), Perfluorodecanoic acid (PFDA), Perfluoroundecanoic acid (PFUnA), and
Perfluorododecanoic acid (PFDoA)] and thyroid stimulating hormone (TSH), free and total thyroxine (FT4 and
TT4), free and total triiodothyronine (FT3 and TT3), T3RU (Free triiodothyronine resin uptake) and FT4-index
(FT4I) levels were recorded. We evaluated sampling of maternal TH by trimester, and infant TH by sex
stratification. Reported associations between mother or infant PFAAs and TH were not uniformly assessed in
the selected studies.
Results: Ten out of the fifteen studies examined maternal PFAAs concentration and TSH level. Seven studies
showed significant associations between TSH and exposure to six PFAAs congeners, most of them were
positive. Maternal T4 and T3 were investigated in nine studies and five studies found inverse associations
between exposure to six PFAAs congeners and TH (TT3, TT4, FT3, FT4 and FT4I) levels.
Eight of the fifteen studies investigated PFAAs concentrations and infant TSH. Infant TSH level was significantly
affected in four studies, positively in three studies. Nine studies investigated infant T4 and T3 and seven studies
found significant associations with PFAAs exposure. However, both inverse and positive significant associations
with infant TH were found eliciting no clear direction.
Conclusion: Results indicate a mainly positive relationship between maternal PFAAs concentrations and TSH
levels, and suggestion of an inverse association with T4 and/or T3 levels. Associations of infant TH with PFAAs
concentration were less consistent.
Keywords: Perfluorinated-alkyl-acids, PFAAs, Thyroid hormones, TSH, Maternal, Infant, Mother-child-health,
Human biomonitoring, HBM4EU
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Background
Increasing evidence suggests that in utero exposure to
perfluorinated-alkyl-acids (PFAAs), a subgroup of per-
sistent organic pollutants (POPs), have adverse effects
on fetal growth and development [1]. Exposure to
PFAAs has also been shown to affect the thyroid func-
tion [2–4], decrease vaccination immune response in
children [5, 6], increase the risk of breast cancer [7], and
the development of metabolic syndrome, type 2 diabetes
[8], lipoedema and cardiovascular disease [1, 9, 10].
PFAAs are detected globally in human populations
and wildlife [11–13]. Humans are mainly exposed to
PFAAs through food items and drinking water, but also
by inhalation and dermal exposure [14]. The mean half-
life of serum elimination in humans is 5.4 years for per-
fluorooctane sulfonate (PFOS), 3.8 years for perfluorooc-
tanoate (PFOA) and 8.5 years for perfluorohexane
sulfonate (PFHxS) [15]. Since 2000, several western
countries have made restrictions on the PFAAs produc-
tion [16], but presently only PFOS and PFOA are regu-
lated by the Stockholm Convention on Persistent Organic
Pollutants [17]. Thus, human serum concentrations, espe-
cially for the regulated PFOS and to some degree PFOA,
have decreased during the last decade [18, 19].
PFAAs enter the foetal circulation through placenta
transfer and postnatally the infant is exposed by breast-
feeding [20]. Thus, the foetus is exposed to PFAAs at
highly vulnerable developmental stages [21]. Disruption
of hormonal pathways involving the hypothalamic-
pituitary-thyroid (HPT) and hypothalamic-pituitary-
gonadal (HPG) axes has been hypothesized as a mechan-
ism of action (MoA) and mediating steps between the
effects of PFAAs on foetal growth [22]. Maternal abnor-
mal thyroid function during pregnancy might affect
foetal growth and neural development [23–28]. The
foetus’ thyroid hormone (TH) production does not suf-
fice until midgestation but rely on maternal supply
mainly during the 1st trimester, implying a high demand
on the maternal HPT axis [23].
Maternal thyroxine (T4) and triiodothyronine (T3)
hormones crosses the placenta, but not the maternal
thyroid stimulating hormone (TSH) [29, 30]. In the
pregnant woman, the TH production undergoes dy-
namic and physiological changes: TSH decreases during
the 1st trimester and stabilizes in the 2nd and 3rd tri-
mester [31]. The European Thyroid Association guide-
lines recommend a TSH upper reference limit of 2.5
mIU/L in the 1st trimester and 3.0 mU/ L in the second
and third trimesters [32], though it is discussed whether
the limits are too narrow [31]. In the absence of pre-
existing thyroid disease, the American Thyroid Associ-
ation guideline recommends upper limit of 4mIU/L in
early pregnancy week 7–12 and gradually during 2nd
and 3rd trimesters a return to non-pregnancy range
[33]. High human corionic gonadotropin possess a thy-
rotrophic effect and elicit a physiological increase in
levels of T4 and T3. High oestrogen levels in pregnancy
increase circulating levels of thyroxin binding globulin
(TBG), and may lead to an increase in the total level of
T4 and T3 [34, 35]. The thyroid binding capacity is facili-
tated by several plasma proteins such as TBG, transthyre-
tin (TTR) and albumin [36]. Thyroid peroxidase (TPO) is
a key enzyme of TH biosynthesis in the thyroid gland [37].
Thyroid peroxidase-antibodies (TPOAb) may potentially
be an important covariate. TPOAb production during
pregnancy might be indicative of thyroid stress especially
when levels are above a cut-off value [26].
This review will focus on exposure to PFAAs and
thyroid hormone homeostasis in the mother and infant.
Effect estimates were evaluated with the objective to
understand whether PFAAs exposure is related to
hypothyroidism (low free T4, high TSH) or hyperthy-
roidism (high free T4, low TSH).
Method
The PubMed database was searched, using Medical Sub-
ject Headings (MESH) terms and specific keywords, to
locate relevant publications, following a specific strategy
(Table 1). Last literature search was conducted on the
21th January 2020. Citations from selected publications
were also investigated. This report was restricted to epi-
demiological studies with a sample size > 100 partici-
pants. All selected studies are summarized in Tables 2,
3, 4, 5, 6, 7, 8, 9, and 10.
Data extraction
Following data was extracted to supply general informa-
tion and study characteristics (Table 2): Study design
and population, year of enrollment, number of partici-
pants, exclusion criteria, biological matrix for exposure
assessment, pregnancy trimester of exposure assessment
and TH outcome measurement, PFAA compounds
examined above the limits of detection/quantification
(LOD/LOQ), outcome estimates and confounders.
Tables 3 and 4 give the information on exposure, in-
cluding trimester of PFAAs measurement, participants,
median concentration (ng/mL) and % < LOD/LOQ. Ta-
bles 5 and 6 give the maternal and infant TH levels, re-
spectively. Tables 7, 8, 9 and 10 show the original data
on thyroid hormone outcome upon PFAAs exposure.
Results
Study populations
We found 15 original publications that fulfilled the inclu-
sion criteria [38–52] (Table 2). Study populations varied
from 118 to 1366 participants [40, 51], conducted in Asia
(n = 6), Europe (n = 6) and Northern America (n = 3).
Study designs were cross sectional and/or cohort studies.
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Most studies adjusted for maternal age and/or parity
(Table 2).
PFAAs exposure measurement
Tables 3 and 4 show the PFAAs level in mothers and in-
fants, respectively. PFAAs exposure was assessed in ma-
ternal plasma or serum (10 studies, Tables 2 and 3)
collected in 1st trimester (n = 2) [39, 40], 2nd trimester
(n = 5) [38, 41–43, 45] or 3rd trimester (n = 4) [38, 44,
46, 47]. One study measured the maternal PFAAs level
between 24 and 41 weeks of gestational age (2nd, 3rd tri-
mester) or within 5 days after delivery [38]. PFAAs were
also assessed in cord blood serum / plasma (n = 6) [46,
48–52] (Tables 2 and 4).
In all studies, PFAAs were measured using liquid chro-
matography mass-spectrometry techniques. We have in
this review focused on seven PFAAs congeners ((n) stud-
ies): PFOS (n = 15), PFOA (n = 15), PFHxS (n = 12), PFNA
(n = 13), PFDA (n = 10), PFUnA (n = 10), and PFDoA (n =
6), although the studies also examined other congeners
[PFHpS, EtFOSAA, MeFOSAA, 6:2 FTS, NEtFOSAA,
NMeFOSAA, PFPeA, PFHpA, PFTrDA, PFTeDA and
PFOS isomers], which were not included in this review.
The range of maternal PFOS median concentration was
4.4 ng/mL [46] to 29.5 ng/mL [40] (Table 3). Among in-
fants, the range of the PFOS concentration was 0.66 ng/
mL [49] to 5.11 ng/mL [51] in umbilical cord blood
serum/plasma (UCB) samples (Table 4).
Thyroid hormone assessment
The measurement of thyroid hormones varied between
the studies, showing mainly TSH, free T4 (FT4), total
T4 (TT4), free T3 (FT3) and total T3 (TT3) levels or
variations hereof, i.e. FT4 index (FT4I), calculated from
TT4 and T3-resin uptake (FT4I = TT4 × T3 resin up-
take) [39, 47].
Maternal TH were measured during the 1st trimester
(n = 3) [38–40], 2nd trimester (n = 2) [41, 42], 3rd tri-
mester (n = 3) [44, 46, 47] or at multiple time points
(n = 2) [43, 45]. Infant TH were assessed postpartum in
cord blood serum/plasma (n = 6) [44, 46, 47, 49, 51, 52]
or infant serum obtained at heel stick up to 7 days post-
partum (n = 4) [38, 39, 48, 50] (Table 2).
Thus, maternal PFAAs exposure and maternal TH
levels were predominantly measured simultaneously with
exception of Kato et al. who measured maternal TH in
the 1st trimester, while PFAAs exposure was measured
after 1st trimester [38] (Table 2).
Tables 5 and 6 shows the maternal and infant TH levels,
respectively. The maternal TSH median levels were in
general lower than the upper reference limit with no obvi-
ous trimester differences. In general similar TT3 and FT3
levels were observed among the reviewed studies, as ex-
pected with lower FT3 (pmol/L) levels than the TT3
(nmol/L) levels. Also the FT4 and TT4 levels were in over-
all similar among the studies with significantly higher TT4
levels (Table 5). Four studies [39, 42, 43, 45] also deter-
mined the maternal TPOAb finding positive levels.
As shown in Table 6, infant TSH median levels were
in general within the normal reference range (i.e. being
higher than the lower limit but lower than the upper
limit). Moreover, as expected for the T3 (TT3 and FT3),
the TT3 levels were higher than FT3. Similar values of
T4 (TT4 and FT4) levels were also seen among the stud-
ies and FT4 levels were mainly within the lower limit
range (Table 6).
Association between PFAAs exposure and thyroid
hormone outcomes
The associations between PFAAs exposure and TH
outcomes are outlined by the following order: i) ma-
ternal TSH (Table 7), ii) maternal T4 and T3
(Table 8), iii) infant TSH (Table 9) and iv) infant T4
and T3 (Table 10). Maternal TH estimates were
assessed by the trimester in which they were mea-
sured. Infant TH estimates were assessed upon strati-
fication by sex (Suppl. Tables 1 and 2).
Maternal PFAAs exposure and TSH levels (Table 7)
Two out of nine studies (Table 7) showed a signifi-
cantly positive association between maternal PFHxS
concentrations and TSH levels in the 3rd trimester
Table 1 Literature search strategy
Database MESH and non-MESH terms Hits
Pubmed, sorted by ”Best Match” (Perfluorinated OR Perfluorinated acid OR perfluorooctane sulfonic acid OR
perfluorooctanoic acid OR fluorocarbons OR polyfluorinated OR polyfluoroalkyl
OR perfluoroalkyl Perfluorochemicals OR PFOS OR PFOA OR PFNA OR PFDA
OR PFHxS OR PFUnA OR PFOSA OR PFDA)
17,054
AND (Thyroid OR Thyroid hormones OR thyroxine OR triiodothyronine OR
thyroid-stimulating hormone OR TSH OR T4 OR T3)
223
AND (Pregnancy OR maternal OR mother OR newborn OR infant OR cord) 59
Studies full filling inclusion criteria Participants Pregnant women and/or infants with measurements of PFAAs exposure
and thyroid hormones.
20
Number > 100 participants. 15
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Effect estimate TH PFHxS PFOS PFOA PFNA PFDA PFUnA PFDoA




Linear regression: Adjusted β
(p value)








Difference in maternal TH levels
per quartile (Q2–4 vs. Q1) of
PFAA concentrations (95% CI)
FT4Ic ↓ Q2: −0.25
(− 3.55, 3.16)






↓ Q2: − 1.94
(−5.48, 1.72)
– – –
↓ Q3: − 0.35
(− 3.77, 3.18)




↓ Q3: − 0.53
(− 3.79, 2.85)
– – –
↓ Q4: − 4.19
(− 7.43,
− 0.85)*






↓ Q4: − 1.06
(− 4.27, 2.25)
– – –






























































Linear regression: Adjusted β
(95% CI)




































































FT3 ↑: 0.124 ↑: 0.025 ↑: 0.024 ↓: − 0.063 ↓: − 0.087 ↓: − 0.121 ↓: − 0.268*
FT4 ↑: 0.038 ↓: − 0.057 ↑: 0.000 ↓: −0.072 ↓: − 0.086 ↓: − 0.062 ↓: − 0.160*
TT3 ↑: 0.084 ↑: 0.008 ↑: 0.102 ↓: −0.018 ↓: −0.079 ↓: − 0.097 ↓: − 0.301*





Percent change in thyroid
hormone levels per doubling
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[44] or at multiple time points [45]. Two out of ten
studies found an inverse association between PFOS
and maternal TSH levels (in the 1st [38] and 3rd tri-
mester [46]). However, two other studies found PFOS
significantly positively associated with maternal TSH
levels at the 2nd trimester [41] and at multiple time-
points [43], respectively. In fact, women with the
highest PFOS concentration had a significant 24%
higher TSH levels than those with the lowest PFOS
concentration at multiple time points (data not
shown) [43].
No significant associations were found between mater-
nal PFOA concentration and TSH levels (Table 7).
Among nine studies, one study found a positive associ-
ation between PFNA concentration and maternal TSH
levels (Table 7) in the 2nd trimester [42], while another
study found an inverse association within 3rd trimester
TSH [46].
One out of seven studies found a significant inverse
association between PFDA and maternal 3rd trimester
TSH levels (Table 7) [46].
The association between maternal PFUnA and TSH
was examined in six studies (Table 7), and Yang et al.
2016 [46] observed a significantly inverse association
in the 3rd trimester. In the same study [46] the ma-
ternal PFDoA concentration and TSH level were as
well found inversely associated in the 3rd trimester
(Table 7).
Maternal PFAAs exposure and T4 and T3 by trimester
(Table 8)
Maternal T4 and T3 were assessed by nine studies
(Table 8). Significantly inverse associations were ob-
served between maternal FT4 effect estimates (FT4I)
and PFHxS levels in the 1st trimester [39] and at mul-
tiple time points [45]. Although positive tendencies were
found, none of the results were significant for PFOS ex-
posure and maternal T4 and T3 levels (Table 8). Out of
nine studies, investigating the association maternal
PFOA concentration with T4 and T3 levels (Table 8),
one study found a significantly inverse association with
maternal 1st trimester FT4I levels when comparing the
2nd and 4th quartiles with the lowest exposure quartile
[39]. Among the eight studies evaluating maternal PFNA
concentrations and T4 and T3 levels (Table 8), one
study found that PFNA concentrations inversely associ-
ated with maternal FT4 and TT4 levels at the 3rd tri-
mester [44]. Among six studies (Table 8), one study
reported a positive association of PFDA and maternal
TT3 in the 3rd trimester [44], while another study ob-
served a significantly negative association of high PFDA
concentration (4th quartile) and TT3 at multiple time




Effect estimate TH PFHxS PFOS PFOA PFNA PFDA PFUnA PFDoA




Mixed effects model estimated
mean differences in thyroid
hormone concentrations over
time (2nd trimester, at birth and
6 weeks postpartum). Change
across exposure quartiles
(Q1 reference). NS: results
not stated.

















TT4 NS NS NS NS NS NS –




Overall main effect of PFAAs on
TH (all timepoints) from mixed


























TT3 (total triiodothyronine), FT3 (total triiodothyronine), TT4 (total thyroxine), FT4 (free thyroxine), FT4I (free thyroxine index), ↓ decreasing, ↑ increasing, bold
format and star* indicate significant results P < 0.05, NS: results not stated, −: PFAAs not examined, Q1 (1st quartile), Q2 (2nd quartile), Q3 (3rd quartile), Q4 (4th
quartile), IQR (interquartile range)
PFAAs include: PFOS Perfluorooctane sulfonate, PFOA Perfluorooctanoate, PFHxS Perfluorohexane sulfonate, PFNA Perfluorononanoic acid, PFDA Perfluorodecanoic
acid, PFUnA Perfluoroundecanoic acid, PFDoA Perfluorododecanoic acid
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points [43]. Out of five studies assessing maternal T4
and T3 (Table 8), only one showed that FT3 measured
at multiple time points decreased with high PFUnA con-
centrations (4th quartile) [43], while another study found
inverse association between FT4 and TT4 and PFUnA
exposure in the 3rd trimester [44]. Maternal T4 and T3
versus PFDoA exposure were assessed by three studies
(Table 8); two studies observed a significantly inverse as-
sociation with maternal 3rd trimester FT3, TT3, FT4
and TT4 levels [44, 46].
PFAAs exposure and infant TSH level (Table 9)
PFHxS exposure elicited no significant association and
no clear trend after examining four studies with infant
TSH data (Table 9).
Evaluating the PFOS exposure data in the 3rd trimes-
ter or cord blood, the infant TSH levels were examined
in eight studies (Table 9). Maternal 3rd trimester [38,
47] and cord blood PFOS concentrations [51] were sig-
nificantly positively associated with infant TSH levels
(Table 9). But, an inverse association was found in an-
other study assessing PFOS in cord blood and infant
TSH [52]. Upon stratification by infant sex, three studies
found positive associations among boys [38]: βmale =
0.205, p = 0.014, [47]: % change per doubling in PFOS =
39.5, 95%CI (0.4, 94.1) [51]: βmale = 0.333, 95%CI (0.012,
0.678)] (Suppl. Table 1a). While among female infants,
one study found positive [38] [βfemale = 0.173, p = 0.021]
and one inverse [52] [βfemale = − 0.016, 95%CI (− 0.032,
− 0.002)] association, respectively (Suppl. Table 1b).
Using cord blood or maternal 3rd trimester PFOA ex-
posure, the association of PFOA with infant TSH was
examined in eight studies (Table 9). A positively signifi-
cant association was found in one study with maternal
3rd trimester PFOA concentrations [47], while negative
non-significant tendencies were seen in several other
studies [38, 44, 46, 48, 49].
Infant TSH was assessed upon PFNA exposure in
seven studies (Table 9), and a positive association was
seen with maternal PFNA concentrations at the 3rd tri-
mester [47], while an inverse association was found with
cord blood PFNA concentrations [52]. When stratifying
by infant sex (Suppl. Table 1a and b), for males, a signifi-
cantly positive association with maternal 3rd trimester
PFNA concentrations [% change per doubling in PFNA-
male = 60.6, 95%CI (15.0, 124.6)] [47] and an inverse asso-
ciation with cord blood PFNA concentrations [βmale = −
0.166, p = 0.018] [48] was found. Among girls, a similar
pattern for TSH was seen with a positive association
with maternal 3rd trimester PFNA concentrations [%
change per doubling in PFNAfemale = 46.7, 95%CI (5.9,
103.2)] [47] and an inverse association with cord blood
PFNA concentrations [βfemale = − 1.69, 95%CI (− 3.31, −
0.08)] [49].
Infant TSH (Table 9) was found positively associated
with maternal 3rd trimester PFDA concentrations [47],
while an inverse association was found with cord blood
PFDA concentrations [52]. Other studies also showed
decreasing tendencies (in maternal and cord blood),
however the associations were non-significant [44, 46,
49]. When stratifying by infant sex (Suppl. Table 1a and
b), infant TSH was positive associated with maternal
PFDA in 3rd trimester concentrations among boys [%
change per doubling in PFDAmale = 37.0, 95%CI (0.5,
86.8)] [47].
The relation between infant TSH level and PFUnA
concentration were examined in six studies (Table 9)
and one study showed a significantly inverse association
with cord blood PFUnA concentrations [52].
Among five studies that examined cord blood PFDoA
concentration and infant TSH level (Table 9), one study
found a significantly inverse association [52]. After
stratification by infant sex, the inverse association was
only significant among boys [52] [βmale = − 0.062, 95%CI
(− 0.108; − 0.017)] (Suppl. Table 1a).
PFAAs exposure and infant T4 and T3 levels (Table 10)
PFHxS exposure and infant T4 and T3 levels were evalu-
ated by six studies (Table 10) and a study found high
maternal PFHxS levels (4th quartile) were significantly
inversely associated with infant TT4 levels [39]. After
stratification by infant sex, this TT4 association
remained significant only among males [Q4: βmale = −
2.51, 95%CI (− 3.99, − 1.04)] [39] (Suppl. Table 2a).
Whereas, cord blood PFHxS levels were associated with
increased female infant TT3 levels [βfemale = 4.28, 95%CI
(0.39, 8.17)] [49] (Suppl. Table 2b).
The assessement of PFOS exposure and infant T4 and
T3 found in four studies significant associations
(Table 10). High PFOS concentration in the 1st trimes-
ter (4th quartile) [39] and in cord blood [51] was in-
versely associated with infant TT4 levels (Table 10). In
contrast, maternal 3rd trimester PFOS concentration
[46] was significantly and positively associated with in-
creased infant TT3, FT3 and TT4 levels. Likewise, infant
cord blood PFOS concentrations [52] was positively as-
sociated with FT3 levels (Table 10). Upon stratification
by infant sex, the significant inverse associations with
TT4 remained only among boys ([Q4 βmale = − 2.20,
95%CI (− 3.74; − 0.66)] and [βmale = − 0.667, 95%CI (−
1.28; − 0.05)]) [39, 51] (Suppl. Table 2a), while one study
found a positive association with FT4I among girls [%
change per doubling in PFOSfemale = 13.2, 95%CI (0.9,
27.1)] [47] (Suppl. Table 2b).
One study, out of nine, found infant TT4 levels (Table 10)
to be significantly and inversely associated with higher ma-
ternal PFOA concentration (4th quartile) in the 1st trimes-
ter [39]. After stratification by sex, the significance for TT4
Boesen et al. Environmental Health          (2020) 19:107 Page 21 of 28
remained only among boys [Q4 βmale = − 1.72, 95%CI (−
3.36; − 0.08)] [39] (Suppl. Table 2a). Another study found
that cord blood PFOA concentration was positively associ-
ated with FT4 in males [52] [βmale = 0.062, 95%CI (0.024;
0.138)] (Suppl. Table 2a). Whereas, increased TT4 levels
were found in girls with the highest cord blood PFOA con-
centration (4th quartile) [Q4 βfemale = 38.6, 95%CI (13.34;
63.83)] [50] (Table 10, Suppl. Table 2b).
Infant T4 and T3 versus PFNA exposure was investi-
gated in seven studies (Table 10) and one study found that
infant TT3 and TT4 were negatively associated with ma-
ternal PFNA concentrations at 3rd trimester [44]. After
stratification by sex, FT4 was found positively associated
with cord blood PFNA concentration in boys [52] [βmale =
0.04, 95%CI (0.006, 0.081)] (Suppl. Table 2a).
Five studies investigated the infant T4 and T3 levels ver-
sus PFDA exposure (Table 10). Wang et al. 2014 demon-
strated that maternal 3rd trimester PFDA concentration
was inversely [44] and Yang et al. 2016 found a positively
[46] association with infant TT3 levels. Likewise, infant
TT4 and FT4I were positively associated with maternal
3rd trimester PFDA concentrations [46, 47]. After stratifi-
cation by infant sex, FT4 was found positively associated
with cord blood PFDA concentrations for males [52]
[βmale = 0.043, 95%CI (0.016; 0.078)]. Moreover, a positive
association between PFDA and FT4I in males was ob-
served [% change per doubling in PFDAmale = 11.5, 95%CI
(1.5; 22.6)] [47] (Suppl. Table 2a).
In two out of six studies significant data was found for
exposure to PFUnA and association to infant T4 and T3
levels (Table 10). Maternal 3rd trimester PFUnA concen-
tration was associated inversely with TT3 and TT4 infant
levels in one study [44], and another study found increas-
ing infant TT4 levels [46]. Tsai et al. found no effect in the
total study population but a significant positive association
when examining the 60th–89th percentile of cord blood
PFUnA concentration with infant T3 levels [β = 0.197,
95%CI (0.031;0.364), P < 0.05] (data not shown) [51].
For PFDoA exposure versus infant T4 and T3 levels two
of five studies found significant associations (Table 10). An
inverse association with maternal 3rd trimester PFDoA was
found in one study [44]. Cord blood PFDoA concentration
was found negatively associated with infant FT3 but posi-
tively with FT4 [52]. After stratification by infant sex, FT4
was positively associated with cord blood PFDoA concen-
tration in both boys and girls ([βmale(FT4) = 0.54, 95%CI
(0.019; 0.119)], [βfemale(FT4) = 0.174, 95%CI (0.019; 0.331)]
[52], but for FT3, the inverse significant association
remained only among girls [βfemale(FT3) = − 0.124, 95%CI
(− 0.185; − 0.056)] [52] (Suppl. Table 2a and b).
Discussion
This literature review suggests that PFAAs exposure can
influence maternal TSH levels. Moreover, several PFAAs
were inversely associated with maternal T4 and T3
levels. The studies reported some associations between
PFAAs exposure and infant TH levels although the data
was less conclusive.
TSH
PFHxS, PFOS, PFNA, PFDA, PFUnA and PFDoA expos-
ure seem to affect maternal TSH levels; however, only
PFHxS, PFOS and PFNA were found significantly associ-
ated with TSH in more than one of the reviewed studies.
Thus, five studies found significant increased maternal
TSH levels upon exposure to PFOS, PFNA and PFHxS
[41–45], which might indicate a (subclinical) hypothyroid
maternal state. Two studies found significantly decreased
maternal TSH levels with increasing PFOS, PFNA, PFDA,
PFUnA and PFDoA concentrations [38, 46], which might
indicate a hyperthyroid maternal state. None of the ten
studies investigating the association between PFOA con-
centration and maternal TSH found any significant results
[38–47]. However, it should be noted that all these PFAAs
are often highly intercorrelated.
Three studies found increased TSH levels in infant
upon PFOS exposure [38, 47, 51], while one study also
found increased infant TSH levels with PFOA, PFNA
and PFDA concentrations [47]. A single study found de-
creasing infant TSH with PFOS, PFNA, PFDA, PFUnA
and PFDoA concentrations [52]. None of the studies in-
vestigating the association between PFHxS (n = 5) and
infant TSH found any significant associations [44, 46,
47, 49, 52] and seven of the eight studies investigating
the association with PFOA found non-significant results
[38, 44, 46, 48, 49, 51, 52].
T4 and T3
Five studies found decreasing maternal TT3, TT4, FT3,
FT4 and FT4I levels associated with PFHxS, PFOA,
PFNA, PFDA, PFUnA and PFDoA concentrations [39,
43–46]. Low levels of T4 and T3 (and high TSH) could
indicate a hypothyroid maternal state. One study showed
a positive association of maternal TT3 upon PFDA ex-
posure [44].
Four studies found decreasing infant TT4, TT3 and
FT3 with exposure to any of the investigated PFAAs [39,
44, 51, 52], and four studies found increasing infant FT3,
FT4, FT4I, TT3 and TT4 levels with exposure to PFOS,
PFOA, PFDA, PFUnA and PFDoA [46, 47, 50, 52].
In overall, most studies showed a positive association
of maternal TSH and a possible negative association of
maternal T4 and T3 upon PFAAs exposure. This indi-
cates that pregnant women may be at risk of developing
a hypothyroid state with increasing PFAAs exposure. In-
fant TH might also be affected, mainly increasing infant
TSH levels with PFOS. More studies are needed to
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determine the direction of the association with infant T4
and T3 levels.
Evaluation of TH across pregnancy trimesters with PFOS
and PFOA exposure
During the 1st trimester, most studies on maternal TH
[38, 39] (Table 7) showed that TSH was inversely related
with PFOS, although, only one reached statistical signifi-
cance [38]. Non-significant positive relationships were
found with PFOA concentrations. PFOS and PFOA con-
centrations was mainly non-significantly but positively
associated to maternal FT4 levels [38, 40] and TT4 levels
[39] (Table 8). FT4I was inversely associated to PFOA
but not significantly to PFOS [39].
In the 2nd trimester, studies on maternal TH [41, 42]
(Table 7) showed that TSH was positively associated
with PFOS exposure, being statistically significant in one
study [41]. No consistency was found for the relation be-
tween PFOA and TSH, with both positive and inverse
non-significant associations [41, 42]. Moreover, results
on maternal T4 (Table 8) did not show any significant
associations [42].
In the 3rd trimester, studies on maternal TH [44, 46,
47] (Table 7) demonstrated that TSH was significantly
and inversely associated with maternal PFOS concentra-
tion in one study [46]. No consistent direction was
found for PFOA exposure. For the maternal T4 and T3
levels [44, 46, 47] (Table 8), FT4, TT4, FT3 and TT3
were mainly positively, but non-significantly, associated
with PFOS and PFOA.
Two studies conducted a longitudinal assessment of
TH measurements across the trimesters and postpartum
(Tables 2, 7 and 8) [43, 45]. Repeated measurements of
maternal TSH were positively associated with PFOS ex-
posure being significant in one study [43] (Table 7). A
non-significantly inverse association was found for FT4,
but positive for FT3 upon exposure to PFOS and PFOA
[45](Table 8).
The trimester data evaluation showed negative associa-
tions between PFOS and maternal TSH in the 1st and
3rd trimester, but positive during the 2nd trimester
(Table 7), whereas PFOA exposure did not elicite signifi-
cant association to TSH in any of the trimesters. The tri-
mester data evaluations for maternal T4 and T3 versus
PFOS and PFOA concentrations showed inverse associ-
ation between PFOA and FT4I in first trimester [39]
(Table 8). Longitudinal TH studies found a positive asso-
ciation between TSH and PFOS [43] while data on
PFOA exposure did not imply a strong association with
maternal thyroid hormones. It must be noted that only
few studies with information on each trimester were
found, thus, the direction of the estimates might change
when more studies are performed. Interestingly, it has
been shown that associations of maternal TSH with
exposure to PFHxS and branched PFOS isomers were
strongest in early pregnancy (1st trimester) and weak-
ened over subsequent trimesters (data not shown) [45].
Stratifying by infant sex
Seven studies stratified on infant sex [38, 39, 47–49, 51,
52] (Suppl. Tables 1 and 2).
PFOS concentration was positively and significantly
associated with TSH levels in boys [38, 47, 51] and girls
[38]. PFNA was found to be inversely significantly asso-
ciated with TSH levels in boys [48] and girls [49], while
another study found positive associations in both gen-
ders [47] (Suppl. Table 1a-b). One study observed a
negative association of TSH with cord blood PFOS ex-
posure in girls and PFDoA in boys (Suppl. Table 1a-b)
but they did not perform the statistical analysis on all
PFAAs congeners in each sex due to their choice of stat-
istical model (sparse partial least squares) [52].
In boys, TT4 levels were inversely associated with
three PFAAs congeners (PFHxS, PFOS and PFOA) mea-
sured in maternal blood and cord blood samples (Suppl.
Table 2a) [39, 51] and PNFA maternal concentrations
were positively associated with FT4I [47]. In girls, TT3
levels were positively associated with cord blood PFHxS
[49], and FT4I and TT4 levels positively associated with
maternal PFOS and PFOA and cord blood PFOA (high-
est quartile) [47, 50] (Suppl. Table 2b). In boys, a study
found significant positive associations for FT4 with sev-
eral cord blood PFAAs (PFOA, PFNA, PFDA, PFDoA)
concentration (Suppl.Table 2a), the analysis was however
not performed in girls due to their choice of statistical
model (sparse partial least squares) [52]. In the pooled
infant analyses (Table 10) this study observed similar
significant positive association between FT4 level, but in-
versely association with FT3 level, and cord blood
PFDoA concentration [52].
The reviewed studies do not allow us to establish a
distinct tendency or greater sensitivity regarding infant
sex. Further studies must be conducted to state any con-
clusion on gender specific sensitivity for PFAAs expos-
ure and TH disruption.
Previous review literature
The possible link between PFAA exposure and thyroid
outcomes in pregnant women was previously reviewed
by Ballesteros et al. in 2017 [53]. They included 10 epi-
demiological studies on PFOS, PFOA, PFHxS and PFNA
exposure during prenatal life, childhood and adolescence
(up to 19 years), with sample size ranging from 40 to >
10.000 participants. In accordance to this current review,
Ballesteros et al. suggested a positive association between
PFHxS and PFOS and maternal TSH levels, as well as,
between PFNA and TSH levels measured in boys aged >
11 years. Compared to Ballesteros et al. [53], the current
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review includes recent epidemiological studies (enrol-
ment year: 1996–2016 vs. 1987–2013), more studies
(n = 15 vs. n = 10), bigger sample size (participants > 100
vs. > = 43) and covers more PFAAs congeners (7 vs. 4),
thus it might add a stronger study power and support to
the previous observations. We also found stronger evi-
dence of a positive relationship between PFAAs expos-
ure (especially PFOS) with maternal TSH, and a possible
inverse relationship with maternal T4 and T3 levels.
Biological plausibility
PFAAs are endocrine disrupting compounds that impact
on endogenous hormone homeostasis [54]. Different
pathways have been suggested to explain thyroid dis-
rupting effects: PFAAs may induce increased excretion
of T4 by alteration of TBG due to competitive binding
[55], and/or increased conversion of T4 to T3 by type 1
de-ionidase in hepatic cells, as well as increased hepatic
metabolism of T4 [56]. PFAAs could furthermore alter
the responsiveness of the HPT axis [57], as well as, alter
the HPG homeostasis and their signaling pathways
which might affect foetal growth [58, 59].
Several animal studies have shown reduced foetal
growth upon PFAAs exposure [60–62]. Furthermore, ani-
mal studies have reported PFAAs disrupted HPT [60, 63,
64] and HPG-axis [65, 66]. However, comparison among
studies is challenged because interspecies diversity (e.g.
half-lives, excretion and plasmatic carrier proteins), PFAA
congeners and levels of exposure, and extrapolation from
animal studies to human risk assessment [64, 67].
Studies have suggested that thyroid and oestrogenic/
androgenic pathways may be a part conjoined mecha-
nisms. In vitro studies have shown that the HPT axis is
affected by PFAAs exposure by inhibiting thyroid recep-
tors, antagonizing thyroid cell proliferation [57]. Further-
more, PFOS and PFOA decreased TPO activity, blocking
the ionizing process of thyroglobin [37], leading to re-
duced T4 and T3 levels. Cell proliferation of the TH-
dependent rat pituitary GH3 cells was shown to be
dependent on the involvement of the oestrogen receptor
[68]. Moreover, in vitro studies have also shown alter-
ations in the biosynthesis of oestrogens and interference
with the oestrogen receptor, after exposure of PFNA,
PFDA, PFHxS, PFOS and PFOA, due to their
oestrogenic and anti-androgenic potential [2, 69–71].
Extracted PFAA mixtures from human serum samples
also activated oestrogenic receptors [72, 73] and in an
epidemiological study serum PFAAs mixture induced es-
trogenic activity in pregnant women was associated with
significantly lower birth weight and birth length [58].
Most studies examined the effect of single PFAA conge-
ners. More studies are needed for the combined cocktail
effect of PFAAs mixtures and/or other POPs, which may
have additively and/or synergistic actions [58, 73].
PFAAs exposure and TH outcome assessment
All the reviewed studies determined PFAA concentra-
tions, using small variations of the same methodology
(liquid chromatography-tandem mass spectrometry), in
mother and/or infant. Maternal biological matrix was ei-
ther blood plasma or serum and for infant concentra-
tions either cord blood plasma or serum. The LOD and
LOQ values were different among studies. The percent-
ages of samples below LOD/LOQ varied among studies,
especially for PFHxS, PFNA, PFDA in maternal serum/
plasma samples (Table 3) and for most PFAA congeners
in cord blood (Table 4). Nevertheless, most selected
studies handled the PFAA concentrations below LOD/
LOQ with replacement by LOD/LOQ divided by the
square root of 2. The sensitivity of the used methods
might influence the estimated effect but the exposure
levels is expected to be the main factor for the exposure
- outcome associations.
Umbilical cord blood samples were also used to deter-
mine both infant exposure and thyroid function having
the benefit being of representing the fetal environment.
However, there are also some limitations of using cord
blood for infant thyroid function assessment. Firstly, cord
blood thyroid hormone levels likely reflects a combination
of maternal and fetal hyroid hormones. Secondly, mater-
nal and umbilical cord blood PFAAs concentrations are
highly correlated [74, 75], and the ability of PFAAs to
cross the placenta differs between compounds (i.e. PFOA
passes more easily than PFOS [20, 75, 76].
Maternal PFAA concentrations might not be constant
throughout pregnancy due to physiological hemodynamic
changes. PFAAs concentrations decrease during preg-
nancy due to increased plasma volumes [77] and higher
renal PFAAs excretion [78]. Thus, measurement of PFAAs
in late pregnancy might not be directly compared with
PFAAs concentration in 1st trimester [77]. Moreover,
women are able to transfer some of their PFAAs burden
to their offspring by placental [21, 79] and post-partum
breast feeding [80]. This complicates comparison between
studies with different pregnancy time points of exposure
assessment [19]. Even more, one study measured the thy-
roid hormone outcome before exposure (PFAAs) [38],
which could cause concern of causality, although some
retrospective consistency for PFAAs exposure can be as-
sumed due to their persistent nature (long half-lives in hu-
man serum) [15, 18]. However, a study showed the PFAA
concentrations measured in the 1st and 3rd trimester were
highly correlated (r > 0.64) [81] and argued that a single
exposure measurement might be considered as a repre-
sentative of serum levels during pregnancy.
In most of the studies, the exposure was evaluated as
single congeners and not as the real mixture/combined
exposure scenario. PFAAs are often highly inter-
correlated. It is very diffecult to control for confounding
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by other PFAAs when assessing the effect of single
PFAA congeners and interpret the association in light of
the high mutual correlation among PFAA congeners.
However, given the structural analogy and similar ex-
pected modes of action, PFAAs should be regulated as a
chemical family rather than isolated compounds [82,
83]. In this regard, the complementation of exposure
biomarkers with biomarkers of combined biological ac-
tivity to PFAS mixtures in epidemiologic studies may be
of great help [58]. Berg et al. (2017) [84] did not find an
association between summed PFAAs exposure (sum of
PFHpS, PFHxS, PFOA, PFOS, PFNA, PFDA and PFUnA)
and TH outcome. Whereas, high exposure (4th quartile)
to the summed POP (sumPFAAs + sumPCBs [sum of
PCB 99,118, 138, 153, 163, 170, 180 and 187] + DDE +
HCB + cis- and trans-nonachlor) was significantly posi-
tively associated with maternal TSH [84]. A study found
no effect of the summed PFAAs exposure on maternal
risk of hypothyroxinaemia (low free T4 without the
compensatory rise in TSH) [85]. Furthermore, one study
examined branched isomers of PFOS and found several
significant findings, but not with the total PFOS [45].
The selected studies in this review investigated FT4I,
FT4, FT3, TT4, TT3, T3RU and TSH in mothers and in-
fants using different methods of chemoluminescent-, radio-
or enzyme linked immunosorbents assays, with variable
sensitivity (e.g. LOD (TSH) = 0.50 μU/mL [38] vs. LOD
(TSH) = 0.01 μU/mL [41]). The radio immune sorbent
assay seems to be the most reliable method for the quantifi-
cation of thyroid hormones [86], but all methods showed
good sensitivity, specificity, and accuracy. However, the use
of immunosassay for hormone determination has been crit-
icized. Animal studies suggested that the effect of PFOS to
decrease FT4 level might be due to negative bias in analog
techniques resulting from competitive displacement of FT4
and the labeled analog from serum and assay binding pro-
teins in the presence of PFOS [61, 87]. Nevethrthless, such
bias was not observed in human study and such different
result between human and animal study might be related
to the difference of PFAA level, protein binding to T4 (in
rats: TTR, in human: TBG) and the interaction of proteins
and PFAAs [88]. Based on these reported data, the use of
different methods seems not to be of concern in measure-
ments of human thyroid hormones.
Most studies examined TH at a single time point dur-
ing pregnancy, impeding the capture of an effect on the
thyroidal system during pregnancy since levels vary sub-
stantially during different pregnancy stages and stabilises
approximately 6 weeks postpartum [34, 89]. However,
longitudinal studies measure TH outcomes multiple
times having a greater chance of witnessing an effect on
the thyroid system [42, 43, 45].
TSH was examined in all studies except one [50], and
T4 and T3 parameters were less consistently studied.
The free TH reflects the biologically active hormones,
which may give a better estimate of the exposure effect
on the thyroid regulatory systems [90]. The FT4I is an
estimate of circulating free T4 levels, which accounts for
changes in T4 levels due to changes in thyroid binding
protein levels and saturation, such as increases in TBG
during pregnancy [91], being a better estimate, but only
assessed in one single study [39]. Some of the studies
only investigated a single TH parameter [41, 48, 50],
however to understand the effect of PFAA exposure on
the TH equilibrium at least T4 and TSH measurements
are required.
The extent of adjustment for potential confounders var-
ied largely between studies. General confounders were
pre-pregnancy BMI, maternal age, socio-occupational sta-
tus, parity, alcohol and smoking (Table 2). Eight studies
excluded participants with thyroid diseases or related
medication [38, 39, 41–44, 46, 48] and one study adjusted
for these confounders [50]. However, few studies also took
into account other thyroid parameters such as iodine sta-
tus, TPOAb or thyroid binding capacity. Berg et al. dem-
onstrated that several significant effect estimates lost
significance after adjusting for thyroid binding capacity in
the statistical analysis [43], suggesting an area that should
be further studied.
FT4I was suggested as a more reliable FT4 estimate
during pregnancy [39]. Weiss et al. found evidence that
PFAAs might decrease T4 due to their affinity to thyroid
hormone transport proteins using transthyretin (TTR) as
carrier protein [55]. However, Preston et al. did not sup-
port this theory, after showing lower saturation of
plasma binding proteins with higher PFAAs exposure
[39]. The incoherent results may be due to the fact that
experimental studies use TTR as carrier protein, al-
though the major carrier protein in humans is TBG,
which has lower PFAA affinity than TTR [92].
Three studies stratified for TPOAb-status and mater-
nal TSH was associated with several PFAAs in the high
TPOAb group [39, 42, 45]. However, the high TPOAb
groups differed in sample size (e.g. 14 vs. 98 partici-
pants), gestational week (GW) of exposure sampling
(median GW 9.6, GW 15–18 and multiple time points),
TPO-Ab threshold (Webster et al. and Reardon et al.: >
9 IU/mL vs. Preston et al.: > 2 U/mL) and PFAA concen-
trations (lower in Reardon et al). Even though results
went in different directions, it might indicate a more
susceptible group among women with thyroid stress,
whom may not be able to compensate for the
PFAAs-induced thyroid affections [42]. If these
women are highly exposed to PFAAs, which are
strongly suspected to affect the thyroid gland, it could
increase their risk of immune reactivity and affect the
TH production necessary for a normal foetal
development.
Boesen et al. Environmental Health          (2020) 19:107 Page 25 of 28
Conclusion
In overall, most studies supported a positive association
of maternal TSH and a possible negative association of
maternal T4 and T3 upon PFAAs exposure. Infant TH
might also be affected. The trimester data evaluation
showed different direction of associations between PFOS
and maternal TSH in different trimester. A positive asso-
ciation between TSH and PFOS was observed in longitu-
dinal studies. The associations of PFAAs and TH in
infant gender differed and were PFAA congeners
dependent.
PFAAs exposure has a stronger influence on maternal
than infant TH levels. Scientific evidence seems to
favour an increase in maternal TSH and decrease T4
and T3 estimates upon PFAA exposure. The reviewed
studies reported some associations between PFAAs and
infant TH levels, although these data were less conclu-
sive. The data did not indicate a clear trend in infant
gender sensitivity. This review also showed a tendency
of trimester dependency of maternal TSH levels, but
more studies are needed longitually or during the 1st tri-
mester with follow-up at birth with samples from
mother and child (cord blood).
Future studies need a uniform method of examining
the associations. We suggest future studies to focus on
the 1st trimester with longitially followup in nulliparous
women and include a broad range of PFAA congeners.
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